Cyclacel has contributed to many scientific advancements.

Jul 2021

Kantarjian HM et al., Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS). Cancer 2021; doi: 10.1002/cncr.33828.

Apr 2019

Keenan T et al., Expansion of phase 1 study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations. Proc. Ann. Meeting AACR, 2019, Mar 29–Apr 3; Atlanta, GA, Abstract CT050.

Jan 2017

Kantarjian H et al., Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood 2017, 130: Abstract 891.

Jul 2016

Tolaney, SM et al., Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. J Clin Oncol 34, 2016 (suppl; Abstract 2503).

Jan 2013

Shapiro GI et al., Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors. Proceedings of the 104th Annual Meeting AACR; 2013, Apr 6-10; Washington, DC. Philadelphia, PA: AACR; 2013. Abstract LB-202.

Oct 2012

Kantarjian H et al., Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012, 13:1096-1104.

Jun 2011

Ravandi F et al., Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukaemia. J Clin Oncol 29: 2011 (suppl; Abstract 6587).

Apr 2010

Frame S et al., Understanding the pathways involved in the repair of CNDAC induced DNA damage. Proceedings of the 101st Annual Meeting AACR; 2010, Apr 17-21; Washington DC, Abstract 3502.

Nov 2009

Kantarjian H et al., Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010, 28:285-291.

Learn More About Our Science

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.